Sep 07, 2022 / 06:40PM GMT
Peter Verdult - Citigroup Inc., Research Division - MD
Okay. So good afternoon, everyone. It's Peter Verdult here from the Pharma team. Delighted to be hosting Bill Sibold. I don't think he needs an introduction, but just for completeness, Global Head of Specialty Pharma and the President of North America.
Bill, great to have you with us. I thought -- I hope you don't mind, sort of the context of this call where we sort of characterized as the good. Luckily for you, you run most of those businesses. The bad, which is probably the pipeline developments; and the potentially ugly with regards to (inaudible). So that's the sort of theme of the talk for the next 40, 45 minutes. You may choose to disagree and feel free to tell me where I'm wrong. That's the way I'm going to address it.
But perhaps before we do that, are there any high-level comments you want to make before we get into the details. And before we do that, the audience, this is me moderating, not monopolizing. (Operator Instructions) Bill, over to you.
William J. Sibold - Sanofi - Executive VP of
Sanofi SA at Citi BioPharma Conference Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers